Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Trading today

<< Previous

Bullboard Posts

Next >>

Comment by Chritterson Jun 01, 2020 4:03pm

130 Views

Post# 31098156

RE:Trading today

I hear ya I am still in the green by $500 only Thought we would have ended at 0.035 at least. Very frustrating today

Raiders11 wrote: I don't see any interest in KLY as evident in the share price,if this was happening the price would have jumped at the announcement last week,I had a glimmer of hope and was even in the green for about 5 minutes last week,15 million on the ask up to 5 cents,we need a miracle!

<< Previous

Bullboard Posts

Next >>

AI companies to invest in